{"schema_version":"1","generated_at":"2026-11-06T10:20:40.235Z","data_as_of":"2026-11-05","url":"https://www.findmykol.com/kol/carlos-prada","json_url":"https://www.findmykol.com/kol/carlos-prada/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"carlos-prada","name":"Carlos Prada","credential":"MD","title":"Division Head","specialty":"Clinical Genetics (M.D.)","specialty_raw":"Clinical Genetics (M.D.)","therapeutic_area":"Rare/Genetic","therapeutic_areas":["Rare/Genetic"],"institution":"Ann and Robert H Lurie Children's Hospital of Chicago","institution_url":"https://www.findmykol.com/institution/ann-and-robert-h-lurie-children-s-hospital-of-chicago","city":"Chicago","state":"IL","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1386851335","orcid":"0000-0003-3348-3531","openalex":"A5013293147"},"summary":"Carlos Prada is Division Head at Ann and Robert H Lurie Children's Hospital of Chicago. OpenAlex indexes 178 publications with 3,770 citations (h-index 32); ClinicalTrials.gov lists 2 registered studies with this person as an investigator.","overview":{"text":"Carlos Prada, M.D., is Division Head at Ann and Robert H Lurie Children's Hospital of Chicago. The public record shows 178 publications with 3,770 citations (h-index 32), centered on Metabolism and Genetic Disorders, Genomics and Rare Diseases, Lysosomal Storage Disorders Research. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 12 companies, 2 NIH-funded awards (2021–2026).","bullets":["Most recent indexed publication: 2026 · Neurology. Clinical practice","Top research focus: Metabolism and Genetic Disorders","2 registered trials on ClinicalTrials.gov","Open Payments reporting from 12 companies"],"generated_at":"2026-11-05"},"focus":{"indications":[{"label":"Ketosis","therapeutic_area":"Endocrinology/Metabolic","trials":1,"topics":0,"strength":3},{"label":"Phenylketonurias","therapeutic_area":"Endocrinology/Metabolic","trials":1,"topics":0,"strength":3},{"label":"Neurofibromatosis 1","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Neurofibromatoses","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Neurofibroma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Fibroma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Lymphoma","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Acromegaly","therapeutic_area":"Endocrinology/Metabolic","trials":0,"topics":0,"strength":1},{"label":"Neuro-Oncology / Glioma","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Leukemia (AML/ALL/CML/CLL)","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Dyslipidemia / Lipid Disorders","therapeutic_area":"Cardiology","trials":0,"topics":0,"strength":1}],"research_topics":["Metabolism and Genetic Disorders","Genomics and Rare Diseases","Lysosomal Storage Disorders Research","Glycogen Storage Diseases and Myoclonus","Genetics and Neurodevelopmental Disorders"],"drugs_studied":{"total":12,"shown":3,"withheld":9,"rows":[{"name":"Cerdelga","generic":"Eliglustat","trials":0,"payments":16,"publications":1,"mentions":17},{"name":"Xenpozyme","generic":"Olipudase alfa","trials":0,"payments":17,"publications":0,"mentions":17},{"name":"Cerezyme","generic":"Imiglucerase","trials":0,"payments":14,"publications":0,"mentions":14}]},"works_with":{"total":14,"shown":3,"withheld":11,"rows":[{"name":"Genzyme Corporation","trials":0,"payments":130,"mentions":130},{"name":"BioMarin Pharmaceutical Inc.","trials":0,"payments":19,"mentions":19},{"name":"Amicus Therapeutics, Inc.","trials":0,"payments":8,"mentions":8}]}},"scholarship":{"works_count":178,"cited_by_count":3770,"h_index":32,"i10_index":65,"pubmed_count":19,"latest_activity_year":2026,"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT05238909","title":"Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1","status":"ENROLLING_BY_INVITATION","role":"Investigator","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","source_url":"https://clinicaltrials.gov/study/NCT05238909","trial_url":"https://www.findmykol.com/trial/NCT05238909"},{"nct":"NCT04368624","title":"PKU Skin Stripping","status":"COMPLETED","role":"Investigator","sponsor":"Children's Hospital Medical Center, Cincinnati","source_url":"https://clinicaltrials.gov/study/NCT04368624","trial_url":"https://www.findmykol.com/trial/NCT04368624"}],"source":"trials"},"payments":{"company_count":12,"program_years":{"first":2021,"last":2025},"rows_total":30,"shown":3,"withheld":27,"rows":[{"payer":"GENZYME CORPORATION","program_year":2025,"amount_usd":52356.96,"payment_count":28,"source_url":"https://openpaymentsdata.cms.gov/search?query=1386851335"},{"payer":"Amicus Therapeutics, Inc.","program_year":2025,"amount_usd":19955.41,"payment_count":7,"source_url":"https://openpaymentsdata.cms.gov/search?query=1386851335"},{"payer":"BioMarin Pharmaceutical Inc.","program_year":2025,"amount_usd":12391.85,"payment_count":7,"source_url":"https://openpaymentsdata.cms.gov/search?query=1386851335"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1386851335","source":"payments"},"prescribing":{"data_year":2021,"areas_total":1,"areas_shown":1,"areas":[{"area":"Metabolism & gastrointestinal","share_pct":100,"classes_total":2,"classes":[{"class":"Glucosylceramide Synthase Inhibitor","setting":"prescribed","share_pct":53.6,"drugs":[{"name":"Cerdelga","share_pct":100}],"max_beneficiaries":null},{"class":"Hydrolytic Lysosomal Glucocerebroside-specific Enzyme","setting":"prescribed","share_pct":46.4,"drugs":[{"name":"Vpriv","share_pct":100}],"max_beneficiaries":null}]}],"source":"medicare"},"funding":{"award_count":2,"fiscal_years":{"first":2021,"last":2026},"rows_total":3,"shown":3,"withheld":0,"rows":[{"project":"R33NS122094","title":"Developing Novel Biomarkers of Plexiform Neurofibroma Tumor Burden","fiscal_year":2026,"amount_usd":725444,"organization":"LURIE CHILDREN'S HOSPITAL OF CHICAGO","source_url":"https://reporter.nih.gov/quickSearch/R33NS122094"},{"project":"R33NS122094","title":"Developing Novel Biomarkers of Plexiform Neurofibroma Tumor Burden","fiscal_year":2025,"amount_usd":734542,"organization":"LURIE CHILDREN'S HOSPITAL OF CHICAGO","source_url":"https://reporter.nih.gov/quickSearch/R33NS122094"},{"project":"R61NS122094","title":"Developing Novel Biomarkers of Plexiform Neurofibroma Tumor Burden","fiscal_year":2021,"amount_usd":1843151,"organization":"LURIE CHILDREN'S HOSPITAL OF CHICAGO","source_url":"https://reporter.nih.gov/quickSearch/R61NS122094"}],"source":"grants"},"congress":{"count":37,"years":{"first":2004,"last":2026},"societies":["AAN","ACMG Annual Clinical Genetics Meeting","AHA","ASCO","ASH","IDSA","IMMUNOLOGY (AAI Annual Meeting)","ISPOR Europe","WORLDSymposium"],"shown":3,"withheld":34,"rows":[{"title":"P121: Characterizing the burden of gastrointestinal disease in PTPN11-related Noonan syndrome: A single center retrospective cohort study*","society":"ACMG Annual Clinical Genetics Meeting","meeting":"ACMG Annual Clinical Genetics Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1016/j.gimo.2026.103615","source_url":"https://doi.org/10.1016/j.gimo.2026.103615","status":"verified"},{"title":"Current bone screening practices in patients with Gaucher disease in the US: A retrospective cohort analysis of administrative claims data, 2016-2024","society":"WORLDSymposium","meeting":"WORLDSymposium","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1016/j.ymgme.2025.109625","source_url":"https://doi.org/10.1016/j.ymgme.2025.109625","status":"verified"},{"title":"P080: A novel variant and treatment modality in TANGO2 deficiency","society":"ACMG Annual Clinical Genetics Meeting","meeting":"ACMG Annual Clinical Genetics Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1016/j.gimo.2025.102924","source_url":"https://doi.org/10.1016/j.gimo.2025.102924","status":"verified"}],"source":"congress"},"publications":{"total":19,"shown":5,"withheld":14,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"Harmonizing Multi-Institutional Clinical Documentation Using Natural Language Processing in Neurofibromatosis Type 1.","year":2026,"journal":"Neurology. Clinical practice","types":["Journal Article","Observational Study","Multicenter Study"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42585623/","status":"verified"},{"title":"Clinical and Functional Characterization of Gain-of-Function ABL1 Variants Expands the Phenotypic Spectrum of CHDSKM.","year":2026,"journal":"American journal of medical genetics. Part A","types":["Case Reports","Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42681542/","status":"verified"},{"title":"Clinical Experience With Eliglustat in Children With Gaucher Disease Type 1.","year":2026,"journal":"American journal of medical genetics. Part A","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42619358/","status":"verified"},{"title":"Syndrome of the Month: An Update on Smith-Kingsmore Syndrome: Characterization of Developmental Milestones and a Review of the Literature.","year":2026,"journal":"American journal of medical genetics. Part A","types":["Journal Article","Review"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41216843/","status":"verified"},{"title":"Pathogenic UNC13A variants cause a neurodevelopmental syndrome by impairing synaptic function.","year":2025,"journal":"Nature genetics","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41125872/","status":"verified"}],"most_cited":{"total":178,"shown":5,"withheld":173,"rows":[{"title":"Endothelial dysfunction and preeclampsia: role of oxidative stress","year":2014,"cited_by_count":438,"type":"article","source_url":"https://doi.org/10.3389/fphys.2014.00372"},{"title":"Mutations in SLC25A46, encoding a UGO1-like protein, cause an optic atrophy spectrum disorder","year":2015,"cited_by_count":206,"type":"article","source_url":"https://doi.org/10.1038/ng.3354"},{"title":"Pediatric Plexiform Neurofibromas: Impact on Morbidity and Mortality in Neurofibromatosis Type 1","year":2011,"cited_by_count":182,"type":"article","source_url":"https://doi.org/10.1016/j.jpeds.2011.08.051"},{"title":"Loss- or Gain-of-Function Mutations in ACOX1 Cause Axonal Loss via Different Mechanisms","year":2020,"cited_by_count":153,"type":"article","source_url":"https://doi.org/10.1016/j.neuron.2020.02.021"},{"title":"Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition","year":2012,"cited_by_count":141,"type":"article","source_url":"https://doi.org/10.1007/s00401-012-1056-7"}]},"source":"publications"},"presence":{"mentions":{"total":1,"shown":1,"rows":[{"url":"https://www.instagram.com/reel/DPoubR_kU2Y/","label":"Named as featured speaker in Instagram post","status":"provisional"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":2,"shown":2,"rows":[{"value":"Medical degree, Industrial University of Santander","source_url":"https://health.usnews.com/doctors/carlos-prada-621377","status":"provisional","collected_at":"2026-11-05"},{"value":"Board certified Clinical Geneticist","source_url":"https://www.everydayhealth.care/providers/510557/carlos-enrique-prada-md/","status":"provisional","collected_at":"2026-11-05"}]},"secondary_affiliations":{"total":3,"shown":3,"rows":[{"value":"Professor, Northwestern University","source_url":"https://www.doximity.com/pub/carlos-prada-md","status":"provisional","collected_at":"2026-11-05"},{"value":"Division Chief, Genetics, Genomics, and Metabolism, Department of Pediatrics, Northwestern University","source_url":"https://www.pediatrics.northwestern.edu/divisions/genetics/index.html","status":"verified","collected_at":"2026-11-05"},{"value":"Associate Professor, Cincinnati Children's Hospital Medical Center (past)","source_url":"https://orcid.org/0000-0003-3348-3531","status":"verified","collected_at":"2026-11-05"}]},"media":{"total":3,"shown":3,"rows":[{"value":"Featured guest, Cribsiders Episode #137: Connecting the Cafe au Lait Dots: Neurofibromatosis Type 1","source_url":"https://podcasts.apple.com/us/podcast/connecting-the-cafe-au-lait-dots-neurofibromatosis-type-1/id1520185909?i=1000700877622","status":"provisional","collected_at":"2026-11-05"},{"value":"Quoted in trade feature 'Spearheading the Charge Against Rare Disease'","source_url":"https://pharmaboardroom.com/articles/spearheading-the-charge-against-rare-disease/","status":"provisional","collected_at":"2026-11-05"},{"value":"Quoted in NBC Chicago report on $11M gift for rare diseases","source_url":"https://www.nbcchicago.com/news/local/luries-childrens-hospital-receives-11m-gift-to-expand-care-for-rare-diseases/3861352/","status":"provisional","collected_at":"2026-11-05"}]},"public_positions":{"total":2,"shown":2,"rows":[{"value":"Director, NORD Rare Disease Center for Excellence at Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University","source_url":"https://rarediseases.org/center-of-excellence/nord-rare-disease-center-for-excellence-at-ann-robert-h-lurie-childrens-hospital-of-chicago-and-northwestern-university/","status":"provisional","collected_at":"2026-11-05"},{"value":"Consultant for Sanofi-Genzyme and Shire (Takeda), per article disclosure","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9734078/","status":"provisional","collected_at":"2026-11-05"}]}},"similar":[{"name":"Eva Morava-Kozicz","slug":"eva-morava-kozicz","institution":"Icahn School of Medicine at Mount Sinai","specialty":"Clinical Genetics (M.D.)","url":"https://www.findmykol.com/kol/eva-morava-kozicz","json_url":"https://www.findmykol.com/kol/eva-morava-kozicz/profile.json"},{"name":"Virginia Kimonis","slug":"virginia-kimonis","institution":"UC Irvine School of Medicine","specialty":"Clinical Genetics (M.D.)","url":"https://www.findmykol.com/kol/virginia-kimonis","json_url":"https://www.findmykol.com/kol/virginia-kimonis/profile.json"},{"name":"Hope Northrup","slug":"hope-northrup","institution":"UT Health Science Center at Houston","specialty":"Clinical Genetics (M.D.)","url":"https://www.findmykol.com/kol/hope-northrup","json_url":"https://www.findmykol.com/kol/hope-northrup/profile.json"},{"name":"Robert Hopkin","slug":"robert-hopkin","institution":"Cincinnati Children's Hospital Medical Center","specialty":"Clinical Genetics (M.D.)","url":"https://www.findmykol.com/kol/robert-hopkin","json_url":"https://www.findmykol.com/kol/robert-hopkin/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":27,"congress":34,"publications":14}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-11-05"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-11-05"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2025","collected_at":"2026-11-05"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2021},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year","collected_at":"2026-11-05"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-11-05"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-11-05"}},"methodology_url":"https://www.findmykol.com/about#methodology"}